NetworkNewsBreaks – Alpha Cognition Inc. (NASDAQ: ACOG) Prices $35 Million Oversubscribed Public Offering
Alpha Cognition (NASDAQ: ACOG), a commercial-stage biopharmaceutical company focused on treatments for neurodegenerative diseases, announced the pricing of its oversubscribed underwritten public offering of 5.6 million common shares (or pre-funded warrants in lieu thereof) at $6.25 per share, for gross proceeds of approximately $35 million before expenses. The company plans to use net proceeds to accelerate commercialization of ZUNVEYL(R) (Benzgalantamine), including sales expansion, marketing, payer coverage, and reimbursement infrastructure. CEO Michael McFadden said the funding will help maximize near-term adoption while laying the foundation for long-term growth. Titan Partners Group, a division of American Capital Partners, is acting as sole…







